FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.93 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $48,469 | -51.4% | 14,777 | +8.8% | 0.00% | -50.0% |
| Q1 2024 | $99,692 | +115.7% | 13,582 | +9.9% | 0.00% | +100.0% |
| Q4 2023 | $46,215 | +51.9% | 12,357 | -13.9% | 0.00% | 0.0% |
| Q3 2023 | $30,430 | -87.8% | 14,354 | +42.1% | 0.00% | -91.7% |
| Q2 2022 | $250,000 | -38.3% | 10,100 | -3.2% | 0.01% | -40.0% |
| Q1 2022 | $405,000 | +71.6% | 10,434 | +158.8% | 0.02% | +42.9% |
| Q4 2021 | $236,000 | +4.4% | 4,032 | +5.9% | 0.01% | -30.0% |
| Q3 2021 | $226,000 | +5.1% | 3,807 | +53.4% | 0.02% | -13.0% |
| Q2 2021 | $215,000 | – | 2,481 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $11,083,330 | 2.77% |
| Redmile Group, LLC | 13,169,057 | $43,194,507 | 2.61% |
| SUPERSTRING CAPITAL MANAGEMENT LP | 497,360 | $1,631,341 | 2.06% |
| Boxer Capital, LLC | 8,215,910 | $26,948,185 | 1.42% |
| Deep Track Capital, LP | 5,572,607 | $18,278,151 | 0.55% |
| Vestal Point Capital, LP | 2,000,000 | $6,560,000 | 0.49% |
| Bruce & Co., Inc. | 300,000 | $984,000 | 0.32% |
| Octagon Capital Advisors LP | 520,800 | $1,708,224 | 0.27% |
| Integral Health Asset Management, LLC | 850,000 | $2,788,000 | 0.26% |
| Bellevue Group AG | 4,839,779 | $15,874,475 | 0.26% |